Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: Pharmacol Biochem Behav. 2015 Jan 29;131:143–153. doi: 10.1016/j.pbb.2015.01.005

Fig. 7.

Fig. 7

A: Mean (+SEM) activity over the circadian cycle by treatment group during MP treatment. A normal circadian cycle was exhibited by all groups, with no apparent shift in cycle. HD MP treatment resulted in hyperactivity compared to both LD MP and water treatment overall (p <0.05), and at specific times during the dark cycle: 09:00–17:30 (#p <0.05) and 09:30–19:00 (*p <0.05), respectively. LD MP treatment decreased activity compared to controls at a few time points during the dark cycle, 10:00–10:30 and 13:00–13:30 ($p <0.05). B: Mean (+SEM) activity over the circadian cycle by treatment group during abstinence. A normal circadian cycle was exhibited by all groups, with no apparent shift in cycle. HD MP treatment resulted in hyperactivity compared to both LD MP and water treatment overall (p <0.05). C: Mean (+SEM) total activity during the dark and light cycles by treatment group during treatment (TX) and abstinence (AB). During treatment, HD MP resulted in increased activity (vs. water *p <0.001; vs. LD MP #p <0.001) and LD MP resulted in decreased activity during the dark compared to water ($p <0.05). During abstinence, previously-treated HD rats were more active during the dark cycle than water (*p <0.01) and previously-treated LD MP rats (#p <0.01). Dark cycle activity of HD MP rats was greater during treatment than during abstinence (^p <0.001).